COPCOV Investigators
A global network of scientific, medical and research trial collaborators works together on COPCOV, the MORU-led, Oxford-supported study to test if hydroxychloroquine or chloroquine can prevent COVID-19.
As vaccines begin to roll out, finding drugs that prevent COVID-19 is more important than ever: It may be mid-2022 before there are enough COVID-19 vaccines for the 7.5 billion people on this planet. Scientifically proving that hydroxychloroquine provides even a small health benefit could save thousands of lives before vaccines become widely available, and COVID-19 brought under control. Understanding whether these drugs can effectively prevent COVID-19 infection would also support global preparedness for future potential emerging viral threats.
Currently, there are active COPCOV sites in the UK and Pakistan, with new sites opening soon in Indonesia, Nepal, Zambia and in other African countries. In addition, sites in Thailand and Lao PDR are set up, ready to be re-activated should COVID-19 re-emerge there.
Principal Investigators
Investigators
-
Nicholas Day
Professor of Tropical Medicine
-
Bob Taylor
Senior Clinical Research Fellow
-
Elizabeth Ashley
Professor of Tropical Medicine
-
Paul Turner
Associate Professor
-
Arjun Chandna
Research Physician
-
Guy Thwaites
Professor of Infectious Diseases
-
Martin Llewelyn
Professor in Infectious Diseases
-
Amanda Adler
Director, Diabetes Trials Unit
-
Phaik Yeong Cheah
Associate Professor
-
Adrianus Dondorp
Professor of Tropical Medicine
-
Mayfong Mayxay
Vice-President of the Lao University of Health Sciences, Ministry of Health
-
James Callery
Research Physician
-
Piero Olliaro
Professor of Poverty Related Infectious Diseases
-
Sophie Yacoub
Research Group Leader
-
Charlie Woodrow
Honorary Consultant
Trial Researchers
-
Tanya Cope
MORU Head of CTSG
-
Naomi Waithira
MORU head of Data Management
-
Mavuto Mukaka
Associate Professor
-
Maneerat Ekkapongpisit
iTPA Manager